The last time I wrote about Centessa Pharmaceuticals plc (NASDAQ:CNTA), it was in a Seeking Alpha article entitled “Centessa ...

Novo Nordisk's CagriSema Phase 3 data showed 22.7% weight loss, missing the company's own 25% target, causing a 20% drop in ...

The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 URO-901-3005 trial.

William Blair analyst Sami Corwin maintained a Buy rating on Neurogene (NGNE – Research Report) yesterday. The company’s shares opened today at ...

Investors appeared disappointed by CagriSema’s Phase III readout, which showed weight loss that fell short of Novo Nordisk’s ...

It's four o'clock in the morning and I've been walking in a tight circle in my bedroom, on-and-off, for three hours.

StockNews.com assumed coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS – Free Report) in a research note published on Monday morning. The brokerage issued a sell rating on the stock. A number ...

In its anniversary year, Germany’s most important research prize goes to four female researchers and six male researchers / €2.5 million in prize money ... of the cell membrane and the transport of ...

Objective: To evaluate literature reporting on the role of norepinephrine in alcohol withdrawal and to determine the safety and efficacy of α 2-agonists in reducing symptoms of this severe condition.

The approval marks the second for a generic in this class of medications indicated to improve glycemic control in patients ...

The U.S. Food and Drug Administration has approved the first generic version of Victoza (liraglutide injection), ...

Novo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared to ~16% of weight ...